Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

J. P. Machiels; C. René Leemans; W. Golusinski; C. Grau; L. Licitra; V. Gregoire

doi:https://doi.org/10.1016/j.oraloncology.2020.105042

Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

J. P. Machiels, C. René Leemans, W. Golusinski, C. Grau, L. Licitra, V. Gregoire

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Original language	English
Article number	105042
Journal	Oral Oncology
Volume	113
DOIs	https://doi.org/10.1016/j.oraloncology.2020.105042
Publication status	Published - Feb 2021

Keywords

Clinical Practice Guidelines
Diagnosis
Follow-up
SCCHN
Treatment

Access to Document

https://doi.org/10.1016/j.oraloncology.2020.105042

Cite this

@article{ce79e107fce245f391c432b5cdc98fd7,

title = "Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”",

keywords = "Clinical Practice Guidelines, Diagnosis, Follow-up, SCCHN, Treatment",

author = "Machiels, {J. P.} and {Ren{\'e} Leemans}, C. and W. Golusinski and C. Grau and L. Licitra and V. Gregoire",

note = "Funding Information: The EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board would like to thank the Faculty and other experts who provided critical reviews of these EHNS-ESMO-ESTRO Clinical Practice Guidelines. The authors wish to thank Annalisa Trama and Salvatore Alfieri for their constructive contribution during the writing process. Manuscript editing support was also provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. JPM reports acting in an advisory role for Merck Serono and MSD; CRL reports acting in an advisory role for Rakuten Medical and MSD. LL reports participation for public speaking/teaching in medical meetings and/or for providing expert opinion in advisory boards for AstraZeneca, Bayer, BMS, Eisai, MSD, Merck Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy SRL, Doxa Pharma, Amgen, Nanobiotics and GSK. All other authors have declared no potential conflicts of interest. Funding Information: The EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board would like to thank the Faculty and other experts who provided critical reviews of these EHNS-ESMO-ESTRO Clinical Practice Guidelines. The authors wish to thank Annalisa Trama and Salvatore Alfieri for their constructive contribution during the writing process. Manuscript editing support was also provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.",

year = "2021",

month = feb,

doi = "https://doi.org/10.1016/j.oraloncology.2020.105042",

language = "English",

volume = "113",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx

T2 - EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

AU - Machiels, J. P.

AU - René Leemans, C.

AU - Golusinski, W.

AU - Grau, C.

AU - Licitra, L.

AU - Gregoire, V.

N1 - Funding Information: The EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board would like to thank the Faculty and other experts who provided critical reviews of these EHNS-ESMO-ESTRO Clinical Practice Guidelines. The authors wish to thank Annalisa Trama and Salvatore Alfieri for their constructive contribution during the writing process. Manuscript editing support was also provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. JPM reports acting in an advisory role for Merck Serono and MSD; CRL reports acting in an advisory role for Rakuten Medical and MSD. LL reports participation for public speaking/teaching in medical meetings and/or for providing expert opinion in advisory boards for AstraZeneca, Bayer, BMS, Eisai, MSD, Merck Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy SRL, Doxa Pharma, Amgen, Nanobiotics and GSK. All other authors have declared no potential conflicts of interest. Funding Information: The EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board would like to thank the Faculty and other experts who provided critical reviews of these EHNS-ESMO-ESTRO Clinical Practice Guidelines. The authors wish to thank Annalisa Trama and Salvatore Alfieri for their constructive contribution during the writing process. Manuscript editing support was also provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.

PY - 2021/2

Y1 - 2021/2

KW - Clinical Practice Guidelines

KW - Diagnosis

KW - Follow-up

KW - SCCHN

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85096372068&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.oraloncology.2020.105042

DO - https://doi.org/10.1016/j.oraloncology.2020.105042

M3 - Article

C2 - 33239190

SN - 1368-8375

VL - 113

JO - Oral Oncology

JF - Oral Oncology

M1 - 105042

ER -

Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Keywords

Access to Document

Other files and links

Cite this